109 completed, 17 unknown, 9 terminated, 4 recruiting. 148 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 148 | Completed 109, Unknown 17, Terminated 9, Recruiting 4, Withdrawn 4, Not yet recruiting 3, Active not recruiting 2 |
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 178 | 2026-11-01 | 2026-11-05 |
| A Post-Marketing Clinical Trial of Pemafibrate in Patients ο½—ith Hypercholesterolemia and Inadequate Response to Statins Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day, Placebo - Hypercholesterolemia | Phase 4 | Recruiting | Kowa Company, Ltd. | 120 | 2026-07-01 | 2026-07-13 |
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 60 | 2026-05-18 | 2026-06-02 |
| Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet - Acute Coronary Syndromes (ACS), Hypercholesterolemia | Phase 4 | Not yet recruiting | Punjab Institute of Cardology | 120 | 2026-05-01 | 2026-04-09 |
| Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid - Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol | Phase 4 | Completed | Bahria University | 126 | 2026-01-01 | 2026-10-20 |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo) - Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | Phase 4 | Recruiting | Duke University | 6000 | 2025-07-23 | 2026-10-29 |
| LATAM LOWERS LDL-C Usual care, KJX839 - Hypercholesterolaemia | Phase 4 | Recruiting | Novartis Pharmaceuticals | 520 | 2025-02-11 | 2025-12-30 |
| Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population Atorvastatin 10 mg and ezetimibe 10 mg, Atorvastatin 20 mg - Hyperlipidemia (E.G., Hypercholesterolemia) | Phase 4 | Withdrawn | Dr. Md. Alimur Reza | 2025-02-01 | 2026-10-07 | |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
| A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. Inclisiran sodium, BPA - Hypercholesterolemia | Phase 4 | Completed | Novartis Pharmaceuticals | 402 | 2024-06-21 | 2026-07-29 |
| Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides Pitavastatin 4mg, Ezetimibe 10 mg, Placebo (for Pitavastatin/Ezetimibe) - Hypercholesterolemia | Phase 4 | Active not recruiting | JW Pharmaceutical | 88 | 2023-08-21 | 2026-03-02 |
| Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia Inclisiran Sodium, Placebo - Hypercholesterolemia | Phase 4 | Completed | Novartis Pharmaceuticals | 1770 | 2022-04-08 | 2026-04-14 |
| Evolocumab In Advanced Chronic Kidney Disease Trial Evolocumab, Placebo - Chronic Kidney Diseases, High Cholesterol | Phase 4 | Withdrawn | NYU Langone Health | 2021-03-01 | 2022-07-28 | |
| Lipid Management in Renal Transplant Recipients Using Evolocumab. Evolocumab - Hyperlipidemias | Phase 4 | Completed | Brigham and Women's Hospital | 81 | 2021-02-17 | 2026-04-16 |
| Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia Evolocumab, Ezetimibe, Placebo - Hypercholesterolemia, CKD Stage 5 | Phase 4 | Unknown | Policlinico Casilino ASL RMB | 50 | 2020-11-01 | 2020-12-17 |
| Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients Evolocumab, Placebo, Ezetimibe - Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 4 | Unknown | Policlinico Casilino ASL RMB | 50 | 2020-05-04 | 2020-05-26 |
| Effect of Atorvastatin on Carotid Intima Media Thickness Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment - Essential Hypertension, Hypercholesterolemia | Phase 4 | Unknown | Yerevan State Medical University | 200 | 2020-04-15 | 2020-03-13 |
| Effect of Pitavastatin on Bone Pitavastatin - Osteoporosis, Osteopenia, Hypercholesterolemia | Phase 4 | Completed | Seoul National University Bundang Hospital | 70 | 2019-04-08 | 2024-04-11 |
| Impact of LDL-cholesterol Lowering on Platelet Activation Evolocumab - Familial Hypercholesterolemia | Phase 4 | Terminated | Columbia University | 4 | 2018-11-16 | 2021-04-01 |
Showing 20 of 148. Sign in to see all of them.
Atherosclerosis (16) · Cardiovascular Diseases (13) · Dyslipidemias (13) · Coronary Artery Disease (11) · Hyperlipidemias (10) · Coronary Disease (8) · Diabetes Mellitus, Type 2 (8) · Hypertension (8) · Diabetes Mellitus (7) · Hypertriglyceridemia (5) · Inflammation (5) · Insulin Resistance (5) · Hyperlipoproteinemia Type II (4) · Renal Insufficiency, Chronic (4)
Nutritional and Metabolic Diseases (148) · Metabolic Diseases (147) · Lipid Metabolism Disorders (146) · Hyperlipidemias (138) · Dyslipidemias (135) · Vascular Diseases (48) · Cardiovascular Diseases (40) · Arterial Occlusive Diseases (28) · Arteriosclerosis (28) · Myocardial Ischemia (23) · Glucose Metabolism Disorders (21) · Heart Diseases (21) · Pathological Conditions, Signs and Symptoms (18) · Endocrine System Diseases (14) · Pathologic Processes (12)
Atorvastatin (37) · Ezetimibe (35) · Simvastatin (21) · Rosuvastatin Calcium (19) · Ezetimibe, Simvastatin Drug Combination (9) · pitavastatin (8) · evolocumab (7) · Pravastatin (6) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (5) · ALN-PCS (4) · Amlodipine (4) · Colesevelam Hydrochloride (4) · Niacin (4) · alirocumab (4) · Fluvastatin (3)
Organon and Co (18) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Daiichi Sankyo (6) · AstraZeneca (5) · Gachon University Gil Medical Center (5) · Duke University (3) · JW Pharmaceutical (3) · Novartis Pharmaceuticals (3) · Seoul National University Hospital (3) · Yonsei University (3) · Amgen (2) · Bronx VA Medical Center (2) · Danish HIV Research Group (2) · Kumamoto University (2) · Medical University of Graz (2)
United States (32) · South Korea (21) · Japan (12) · Italy (7) · Spain (5) · Denmark (4) · France (4) · Israel (4) · Taiwan (4) · Austria (3) · Belgium (3) · Canada (3) · Czechia (3) · Germany (3) · Norway (3)
Ann-Brit E Hansen, M.D. (2) · Court Pedersen, Professor (2) · Jan Gerstoft, M.D., DMSc (2) · Lawrence Baruch, MD (2) · Ronald M Krauss, M.D. (2) · Alex Laursen, D.M., DMSc (1) · Alex Laursen, M.D., DMSc (1) · Andrea E Satta, MD (1) · Angelo Branzi, MD (1) · Anh Le, PhD (1)
PMID 38018702, PMID 10593347, PMID 11781675, PMID 16404415, PMID 16749654, PMID 16893434, PMID 16923260, PMID 17407633, PMID 17578790, PMID 17668878, PMID 18332269, PMID 18545068, PMID 18559695, PMID 18762410, PMID 19167589, PMID 19286582, PMID 19608026, PMID 19879596, PMID 19939653, PMID 20067513, PMID 20298928, PMID 20339536, PMID 20413733, PMID 20467151, PMID 20617456, PMID 20663203, PMID 20684825, PMID 21122660, PMID 21227624, PMID 21271793, PMID 21297494, PMID 21306285, PMID 21699369, PMID 22115011, PMID 22291820, PMID 22615342, PMID 22621316, PMID 22808006, PMID 22831708, PMID 22913893, PMID 22972364, PMID 23274145, PMID 23289728, PMID 23464930, PMID 23623012, PMID 23863812, PMID 24075764, PMID 24267254, PMID 24339703, PMID 24521776
2004 (1), 2016 (1), R01AR071263 (1), R01HL075824 (1)